List of Atrovent Hfa drug patents

Atrovent Hfa is owned by Boehringer Ingelheim.

Atrovent Hfa contains Ipratropium Bromide.

Atrovent Hfa has a total of 1 drug patent out of which 0 drug patents have expired.

Atrovent Hfa was authorised for market use on 27 November, 2004.

Atrovent Hfa is available in aerosol, metered;inhalation dosage forms.

The generics of Atrovent Hfa are possible to be released after 17 January, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(6 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in